Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soficitinib - InnoCare

Next Previous
Drug Profile

Soficitinib - InnoCare

Alternative Names: ICP-332

Latest Information Update: 18 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoCare Pharma
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Psoriasis
  • Phase II/III Chronic urticaria; Vitiligo
  • Phase II Plaque psoriasis; Prurigo nodularis

Most Recent Events

  • 12 Feb 2026 Phase-II/III clinical trials in Chronic-urticaria (Treatment-resistant) in China (PO) (NCT07378527)
  • 29 Jan 2026 Efficacy and adverse events data from a phase II trial in Atopic dermatitis released by InnoCare Pharma
  • 29 Jan 2026 Beijing InnoCare Pharma completes enrolment in phase-II/III clinical trials in Vitiligo in China (PO) (NCT07047612)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top